Role of LH in ovarian stimulation: Considerations

Reproductive BioMedicine Online

Volumn 12, Issue 4, 2006, Pages 404-406

  Griesinger, Georg ^a   Diedrich, Klaus ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

IVF; LH; Ovarian stimulation; Recombinant FSH; Recombinant LH

Indexed keywords

GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE;

AGING; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HORMONE ACTION; HORMONE INHIBITION; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; NOTE; OBSERVATIONAL STUDY; OVARY FUNCTION; OVULATION INDUCTION; PREGNANCY RATE;

EID: 33645770238     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61990-6     Document Type: Note

References (25)

1. Aboulghar MA, Mansour RT, Serour GI et al. 2004 Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial. Reproductive BioMedicine Online 8, 524-527.
2. Al-Inany H, Aboulghar MA, Mansour RT, Serour GI 2005 Ovulation induction in the new millennium: recombinant follicle-stimulating hormone versus human menopausal gonadotrophin. Gynecological Endocrinology 20, 161-169.
3. Balasch J, Creus M, Fabregues F et al. 2001 The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction. Journal of Assisted Reproduction and Genetics 18, 250-256.
4. Cédrin-Dumerin I, Grange-Dujardin D, Laffy A et al. 2004 Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Human Reproduction 2004 19, 1979-1984.
5. De Placido G, Alviggi C, Perino A et al. 2005 Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction 20, 390-396.
6. Ganirelix Dose-Finding Study Group 1998 A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Human Reproduction 13, 3023-3031.
7. Gomez-Palomares JL, Avecedo-Martin B, Andres L et al. 2005. LH improves early follicular recruitment in women over 38 years old. Reproductive BioMedicine Online 11, 409-414.
8. Griesinger G, Dawson A, Schultze-Mosgau A, Finas D, Diedrich K, Felberbaum R. 2006 Assessment of luteinizing hormone levels in the gonadotropin-releasing hormone-antagonist protocol. Fertility Sterility 85, 791-793.
9. Griesinger G, Schultze-Mosgau A, Dafopoulos K et al. 2005 Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Human Reproduction 20, 1200-1206.
10. Huirne JA, van Loenen AC, Schats R et al. 2005 Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Human Reproduction 20, 359-367.
11. Hull MG, Armatage RJ, McDermott A 1994 Use of follicle-stimulating hormone alone (urofollitropin) to stimulate the ovaries for assisted conception after pituitary desensitization. Fertility and Sterility 62, 997-1003.
12. Humaidan P, Bungum M, Bungum L, Yding Andersen C 2004 Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reproductive BioMedicine Online 8, 635-643.
13. Kol S 2005 To add or not to add LH: considerations of LH concentration changes in individual patients. Reproductive BioMedicine Online 11, 664-666.
14. Kolibianakis EM, Collins J, Tarlatzis B et al. 2006 Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review. Human Reproduction Update 12, 3-12.
15. Lisi F, Rinaldi L, Fishel S et al. 2002 Use of recombinant LH in a group of unselected IVF patients. Reproductive BioMedicine Online 5, 104-108.
16. Ludwig M, Katalinic A, Schultze-Mosgau A et al. 2003. LH supplementation in GnRH-antagonist protocols: preliminary results of a prospective, randomized study. Abstracts of the Annual Meeting of the ESHRE 2003, abstract no. O-008, xviii3.
17. Marrs R, Meldrum D, Muasher S et al. 2004 Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive BioMedicine Online 8, 175-182.
18. Sauer M, Thornton MH II, Schoolcraft W, Frishman GN 2004 Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive BioMedicine Online 9, 487-493.
19. Schoolcraft WB, Sauer MV, Frishman G 2003 Recombinant luteinizing hormone 'add-back' in normogonadotrophic women treated with recombinant follicle stimulating hormone and cetrorelix acetate: a randomized, prospective trial. Fertility and Sterility 80 (S68), abstract no. O-179.
20. Shoham Z The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertility and Sterility 77, 1170-1177.
21. Sills ES, Levy DP, Moomjy M et al. 1999 A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization. Human Reproduction 14, 2230-2235.
22. Tarlatzis B, Tavmergen E, Szamatowicz M et al. 2006. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Human Reproduction 21, 90-94.
23. van Wely M, Westergaard LG, Bossuyt PM, van der Veen F 2003 Effectiveness of human menopausal gonadotrophin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertility and Sterility 80, 1086-1093.
24. Werlin L, Kelly EE, Weathersbee P et al. 1999. A multi-centre, randomized, comparative, open-label trial to assess the safety and efficacy of Gonal-F (r-FSH) versus Gonal-F and recombinant luteinizing hormone (r-LH) in patients undergoing ICSI: preliminary data. Program of the 1999 Annual Meeting of the ASRM, Toronto, Canada, Abstract no. O-032, S12-13.
25. Williams RS 2000 A multi-centre trial comparing the efficacy of recombinant hFSH versus recombinant hFSH plus recombinant hLH in patients undergoing controlled ovarian hyperstimulation for ART. Program of the 2000 Annual Meeting of ASRM, Abstract no. P-428, S228-229.